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(57) ABSTRACT 
A method is provided for detecting an analyte indicative of a 
cancer or a metastatic disease condition, which utilizes the 
ability of the analyte to induce permeability in a barrier. The 
method includes providing a biosensor having a barrier which 
is substantially impermeable to an ion, a permeable mem 
brane which is selective for the ion, and a detector capable of 
detecting the ion. The biosensor is contacted with a sample 
including at least one of the ion and the analyte, wherein the 
analyte causes at least a portion of the ion to pass through the 
barrier and the membrane. Passage of the ion through the 
barrier and membrane allows detection of the ion, providing 
indirect detection of the analyte. In one embodiment, the 
barrier is a cell monolayer, the membrane is selective for 
potassium, and the analyte is vascular endothelial cell growth 
factor. 
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METHODS FOR CANCER DETECTION 
This application claims the bene?t of Provisional Patent 
Application Ser. No. 60/625,875 ?led on Nov. 8, 2004, the 
disclosure of Which is incorporated herein in its entirety by 
reference. 
TECHNICAL FIELD 
The present invention relates to methods for early detection 
of cancer, and for monitoring progression, metastasis, and/or 
treatment ef?cacy of cancer. In particular, the invention pro 
vides a method for detection of cancer comprising detection 
of analytes indicative of cancer or a metastatic disease using 
a biosensor. 
BACKGROUND OF THE INVENTION 
It is knoWn that early detection of cancer is highly corre 
lated With patient survival. Accordingly, research has focused 
on the discovery and recognition of neW diagnostic biomar 
kers that relate to the presence of cancer, its severity, and its 
subsequent progression. Certain biomarkers are speci?c to 
certain cancer types, i.e., prostate speci?c antigen as a diag 
nostic marker for prostate cancer. HoWever, other, non-spe 
ci?c biomarkers have value in early detection of cancer, deter 
mination of prognosis, monitoring of effectiveness of cancer 
treatment, detection of recurrence post-treatment, and the 
like. In this respect, it is knoWn that various cytokines, groWth 
factors, toxins, chemokines, and hormones are found in 
elevated concentrations at the onset of cancer and during 
metastasis of cancer. 
One such cytokine is vascular endothelial cell groWth fac 
tor (V EGF), also called vascular permeability factor (VPF). 
Vascular endothelial cell groWth factor is an endothelial cell 
mitogen, and is knoWn to be present in very small quantities 
in normal human blood in order to facilitate activities such as 
Wound healing. In contrast, soluble VEGF is released in large 
quantities by tumorigenic cells (e. g. carcinomas of the breast, 
large and small intestine, pancreas, kidney, and the like) due 
to its critical role in angiogenesis. During angiogenesis, neW 
blood vessels form from existing vessels to supply nutrients 
to the developing tumor cells. Due to VEGF’s mitogenic 
nature, it facilitates the formation of the neW blood vessels by 
selective action on endothelial cells. 
Quantities of VEGF in serum and plasma of patients With 
tumors from a multitude of cancers (small-cell lung cancer, 
primary breast cancer, non-Hodgkin’s lymphoma, prostate 
cancer, and the like) have been found to be signi?cantly 
elevated. The concentration ofVEGF has also been correlated 
With the presence of metastatic disease, disease stage in col 
orectal cancer, and poor prognosis in patients With small cell 
lung cancer. 
Conventional assays for cytokines such as VEGF for use in 
detecting, diagnosing, or monitoring the progress or progno 
sis of cancer, or for monitoring treatment e?icacy, generally 
rely on speci?c immunological assays for the protein. HoW 
ever, there is a need in the art for a more rapid screening 
method for early detection and monitoring of cancer. The 
screening method should be simple, reliable, and alloW detec 
tion of indices of cancer such as VEGF and other analytes 
knoWn to be produced in elevated quantities during onset, 
progression, and metastasis of various cancers. 
The present invention satis?es this need in the art by pro 
viding methods and systems for detecting and monitoring 
cancer and its progression via detection and quantitation of a 
cytokine using a Whole-cell biosensor. The invention relies on 
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2 
induction of permeability in the cell portion of the biosensor 
to detect and quantitate the cytokine. 
SUMMARY OF THE INVENTION 
In accordance With the purposes of the present invention as 
described herein, in one aspect of the invention a method is 
provided for detecting an analyte indicative of a cancer or a 
metastatic disease condition, comprising providing a biosen 
sor comprising a barrier Which is substantially impermeable 
to an ion, a permeable membrane Which is selective for the 
ion, and a detector capable of detecting the ion. The biosensor 
is contacted With a sample including at least one of the ion and 
an analyte indicative of a cancer or a metastatic disease con 
dition, Wherein the analyte causes at least a portion of the ion 
to pass through the barrier and the membrane to alloW detec 
tion of the presence or absence of the ion and thereby indirect 
detection of the presence or absence of the analyte. 
The barrier is a live cell layer knoWn to be responsive to the 
analyte being detected. In one embodiment of the invention, 
the barrier is a transformed human endothelial cell line, and 
the analyte is VEGF. The cell barrier is typically provided as 
a substantially con?uent cell monolayer Which is contiguous 
With the permeable membrane. In use, the cell monolayer is 
substantially impermeable to the ion, but becomes at least 
partially permeable to the ion upon contact With the analyte. 
The detector may be coupled to a transducer to provide a 
measurable signal upon detection of the ion. 
The analyte being detected Will typically be selected such 
that the amount of the analyte in the sample is indicative of the 
presence, progression, or severity of a cancer or a metastatic 
disease condition, or of the e?icacy of a treatment therefor. 
The analyte may be selected from the group of cancer-related 
analytes consisting of cytokines, groWth factors, hormones, 
chemokines, and toxins, including but not limited to tumor 
necrosis factor, basic ?broblast groWth factor, interleukin 6, 
interleukin 8, hepatocyte groWth factor, or any permeability 
modifying agent released by cancer, and combinations 
thereof. In one embodiment, the analyte detected is VEGF. 
The membrane of the biosensor may be selected to be 
natively selective for the ion of choice, or may be chemically 
modi?ed for selectivity for the ion. The permeable membrane 
may be chemically modifyied using an ionophore to induce 
selectivity for the ion. In one embodiment, a permeable cel 
lulose triacetate membrane is modi?ed With valinomycin to 
induce selectivity for potassium. 
In another aspect of the present invention, a method is 
provided for monitoring the presence, progression or severity 
of a cancer or a metastatic disease, or the e?icacy of a treat 
ment therefor, in a patient during a predetermined time inter 
val, comprising the steps of (l) obtaining a biological sample 
from a patient having or at risk of having a cancer or a 
metastatic disease, (2) combining the biological sample With 
a predetermined amount of an ion to form a mixture, (3) 
contacting the mixture With a biosensor as described above, 
(4) detecting the presence or absence of an analyte Which is 
indicative of a cancer or a metastatic disease condition in the 
mixture, Wherein the analyte causes the live cell barrier to 
become at least partially permeable to the ion Whereby the ion 
is detected by the detector, (5) correlating the amount of the 
ion detected With the quantity of the analyte in the biological 
sample, and (6) repeating steps 1 through 5 over time to 
measure the progress of the cancer or the treatment. It Will be 
appreciated that if the sample naturally contains a knoWn, 
?xed concentration of the ion, inclusion of additional 
amounts of the ion is unnecessary. 
US 7,595,149 B1 
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The biological sample may be selected from the group 
consisting of serum, Whole blood, plasma, saliva, tears, milk, 
urine, other biological/physiological ?uids, a tissue biopsy, 
an organ biopsy, lymphatic ?uid, and any combination 
thereof. The quantity of the analyte detected in the biological 
sample may be then correlated With the presence, progress, or 
severity of the cancer or metastatic disease, or With the e?i 
cacy of the treatment. The biosensor used in this method is 
substantially as described above. In one embodiment, the 
present method comprises use of a biosensor as described 
above, comprising a human umbilical vascular endothelial 
cell line groWn on a cellulose triacetate membrane chemically 
modi?ed With valinomycin to induce potassium selectivity. 
The biosensor is used to detect and quantify VEGF in the 
biological samples. 
In yet another aspect of the present invention, a system for 
detecting the presence of an analyte indicative of a cancer or 
a metastatic disease condition, comprising a cell-based bio 
sensor, anion, and at least one standard sample containing a 
predetermined quantity of an analyte indicative of a cancer or 
a metastatic disease condition. In one possible embodiment, 
the cell-based biosensor comprises a monolayer of human 
umbilical endothelial cells on a cellulose triacetate membrane 
modi?ed for potassium selectivity. The ion is potassium, and 
the analyte is VEGF. The biosensor includes an electrode 
supporting the membrane, With the electrode coupled to a 
transducer Which provides a signal Which can be detected 
upon detection of the ion by the electrode. 
It should be appreciated that the embodiments shoWn and 
described herein are illustrations of some of the modes best 
suited to carry out the invention. It Will be realiZed that the 
invention is capable of other different embodiments and its 
several details are capable of modi?cation in various, obvious 
aspects all Without departing from the invention. Accord 
ingly, the draWings and descriptions Will be regarded as illus 
trative in nature, and not as restrictive. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The accompanying draWings incorporated in and forming 
a part of the speci?cation, illustrate several aspects of the 
present invention and together With the description serve to 
explain the principles of the invention. In the draWings: 
FIG. 1 schematically depicts an embodiment of the biosen 
sor of the present invention; 
FIG. 2 shoWs the preparation of a modi?ed ion-selective 
cellulose triacetate membrane (selective for potassium) and 
attachment of a HUVEC monolayer; 
FIG. 3 shoWs the biosensor response under various condi 
tions: FIG. 3a shoWs the ratio of the electrode response 
obtained at 0.1 M KCl folloWing treatment to the response for 
the membrane Without cells or VEGF at 0.1 M KCl. Experi 
mental conditions Were (A) 1 ug/ml VEGF only, (B) cells 
only, (C) 1 ug/ml VEGF for 2 hr, (D) 1 ug/ml VEGF for 4 hr, 
(E) 1 ug/ml VEGF for 5 hr, (F) 1 ug/ml VEGF for 6 hr (error 
bars represent SEM); FIG. 3b shoWs calibration curves for the 
biosensor under conditions A-F above, With the top line rep 
resenting the average biosensor response Without cells or 
VEGF; 
FIG. 4 shoWs the ratio of the biosensor response folloWing 
exposure to 100 ng/ ml VEGF to the response for the bio sensor 
Without cells or VEGF. Experimental conditions Were (A) 
cells only, (B) after 6 hr exposure, and (C) after 8 hr exposure 
(error bars represent SEM); 
FIG. 5 shoWs the ratio of the biosensor response obtained at 
0.1 M KCl folloWing exposure to 1 ng/ml VEGF to the 
response for the biosensor Without cells or VEGF. Experi 
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4 
mental conditions Were (A) cells only, (B) after 8 hr exposure, 
and (C) after 10 hr exposure (error bars represent SEM); and 
FIG. 6 shoWs the ratio of the biosensor response obtained at 
0.1 M KCl folloWing 10 hr exposure to VEGF concentrations 
ranging from 0 to 1,000 pg/ml, With the data ?tted using 
TableCurve 2D v5 .01 ; also shoWn are the biosensor responses 
to media aspirated from metastatic melanoma cell cultures 
(1205LU) at seeding densities of 1x106, 5x105, and 1><105 
cells/Well; all results are plotted against the average concen 
tration of VEGF as measured by ELISA for the same samples. 
Reference Will noW be made in detail to the present pre 
ferred embodiment of the invention, an example of Which is 
illustrated in the accompanying draWings. 
DETAILED DESCRIPTION OF THE INVENTION 
Conventional methods of cancer detection and monitoring 
often rely on detection of speci?c biomarkers Which may be 
diagnostic of speci?c types of cancer. HoWever, it is knoWn 
that blood concentrations of various cytokines and groWth 
factors, While not necessarily diagnostic of speci?c cancers, 
can be correlated to early stages of cancer, to likelihood 
and/or aggressiveness of metastasis, and to e?icacy of cancer 
treatment. 
It Was considered that a method of rapid screening for such 
cancer-related analytes Would be useful as a general method 
of monitoring presence of cancer, effectiveness of cancer 
therapy, determination of prognosis, and/ or likelihood of 
recurrence. Accordingly, a biosensor-mediated method for 
early detection of cancer, or for monitoring the progress and/ 
or treatment e?icacy of a cancer or a metastatic disease, Was 
developed. As an example, VEGF, a multiple-isoform glyco 
protein Which is a knoWn endothelial cell mitogen, is present 
even during the early stages of cancer and is released in 
soluble form by tumorigenic cells due to its vital role in 
angiogenesis [Ferrara (2004) Endocrine Reviews 25, 581 
611; incorporated herein by reference]. Therefore, in one 
embodiment of the invention, the biosensor utiliZes the ability 
of VEGF to induce permeability of a human endothelial cell 
line monolayer, passage of an ion therethrough, and detection 
of the ion, as an indirect detection method for the analyte. 
In one embodiment, depicted in FIG. 1, the biosensor 10 
utiliZed in the method of the present invention comprises a 
barrier 12 Which is substantially impermeable to an ion, a 
permeable membrane 14 Which is selective for the ion, and a 
detector 16 capable of detecting the ion. In the depicted 
embodiment, the barrier 12 is a human umbilical vein endot 
helial cell monolayer coupled to an ion-selective cellulose 
triacetate membrane 14 by a linker molecule 18. The barrier 
12/membrane 14 complex is carried by the detector 16 to 
provide an ion-selective electrode 20 as Will be described in 
greater detail beloW. A reference electrode 22 may also be 
provided as part of the detector 16 as is knoWn in this art to 
alloW detection of a potentiometric difference in response to 
detection of the ion. 
A sample 24, contained in a receptacle 26, may be con 
tacted With the biosensor 10, Wherein the sample 24 includes 
at least one of the ion and an analyte of interest. It Will be 
appreciated that the analyte Will typically be indicative of a 
cancer and/or a metastatic disease condition, and further 
causes at least a portion of the ion to pass through the barrier 
12 and the permeable membrane 14 to be detected by the 
detector 16. 
The folloWing examples are presented in support of and to 
further illustrate the invention as described herein. HoWever, 
the invention is not to be considered as limited thereto. 
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Example 1 
Referring to FIG. 2, a cellulose triacetate (CTA; Eastman 
Kodak, Rochester, NY.) membrane Was prepared as an ion 
selective support for a cell layer. The base layer of the mem 
brane Was prepared by dissolving 74 mg of CTA pellets in 1.1 
mL of methylene chloride (Aldrich, Milwaukee, Wis.), 0.4 
mL of chloroform (Aldrich), and 0.40 mL of 1,1,2,2-tetra 
chloroethane (Aldrich). The mixed solution Was then cast in a 
31 mm id. glass ring placed on a TEFLON plate. After 
solvent evaporation, the membrane Was removed and ?oated 
on 1.0 M sodium hydroxide for 4.5 hr. Raised edges of the 
membrane ensured that only the loWer surface of the mem 
brane Was hydrolyzed to provide free OH groups. The mem 
brane Was then rinsed With deionized Water. 
A second membrane layer Was cast using an ionophore 
cocktail to induce selectivity for potassium. The ionophore 
cocktail consisted of 1 mg of valinomycin (Calbiochem, San 
Diego, Calif.), a plasticizer (100 ML of o-nitrophenyl octyl 
ether; Fluka, Ronkonkoma, N.Y.), and a lipophilic salt (0.42 
mg potassium tetrakis(chlorophenyl)borate; Fluka) With 35 
mg of CTA. The mixture Was dissolved in a solvent mixture 
composed of 0.80 mL of methylene chloride and 0.80 mL of 
chloroform. The solvent Was alloWed to evaporate for 2 days 
as the tWo membrane layers fused into a single asymmetric 
membrane. 
The bottom side of the basic membrane (having the free 
OH groups) Was immersed in cold deionized Water. Next, 324 
mg of carbonyldiimidazole (CD1; Sigma, St. Louis, Mo.) Was 
added in increments over a 15 min period, giving a ?nal 
concentration of 0.10 M CD1 to activate the surface for pep 
tide coupling. The membrane Was then immediately incu 
bated overnight in a 0.1 M sodium carbonate solution (pH 
9.5) containing 400 pg of a synthetic RGD peptide sequence 
(Bachem, King of Prussia, Pa.) to promote cell binding to the 
membranes. The peptide sequence used Was Gly-Arg-Gly 
Asp-Ser (GRGDS) to promote covalent peptide attachment 
from the N-terminal amine. This is because the arg-gly-asp 
(RGD) segment of ?bronectin is one of the most Widely 
recognized protein sequences to Which human umbilical vein 
endothelial cells (HUVECs) bind. The membranes Were then 
rinsed sequentially With 0.10 M NaHCO3, deionized Water, 
acetate buffer (pH 4.0), and deionized Water. Protein immo 
bilization Was con?rmed using a micro-BCA protein assay 
(Pierce Biotechnology, Rockford, Ill). 
Six mm id. disks cut from the membranes prepared as 
described above Were mounted onto Philips 1S-561 electrode 
bodies (Glasblaserei Moller, Zurich) With the RGD-modi?ed 
surface of the membrane facing the sample solution. Human 
umbilical vein endothelial cells (Cambrex BioScience, East 
Rutherford, N.J.) Were cultured in an EGM-2 media (Cam 
brex BioScience) supplemented With fetal bovine serum, 
hydrocortisone, insulin-like groWth factor, basic ?broblast 
groWth factor, VEGF, human epidermal groWth factor, ascor 
bic acid, human ?broblast groWth factor, gentamicin sulfate, 
amphotericin-B, and heparin. The HUVECs Were used 
experimentally up to passage 5. The HUVECs Were seeded 
onto the bottom surface of the electrode-mounted membrane 
disks at a density of 1><115 cells/mL. The cells Were alloWed 
to spread and form a con?uent monolayer over the membrane 
surface for 24 h at 370 C. in a humidi?ed incubator With 5% 
CO2. 
The internal ?lling solution for the electrode Was 0.01 M 
KCl, and the internal reference electrode Was Ag/AgCl. The 
external reference electrode Was a double-junction Ag/AgCl 
electrode (Orion Model 90-02-00) With an Orion (90-02-02) 
internal ?lling solution and 0.1 M Tris buffer (pH 7.5) in the 
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outer compartment. Potentiometric responses Were measured 
With a four-channel high impedance ampli?er interface 
(World Precision Instruments) connected to a Model 100 
1nstrunet A/ D converter. Data Were analyzed using 1nstrunet 
softWare on a Macintosh PoWer PC. Prior to initial use, the 
electrodes Were conditioned in sterile 0.1 M KCl solution. 
Calibration plots Were constructed by plotting the measured 
potential (mV) versus the logarithm of the concentration of 
potassium ions present in the bulk solution. 
Example 2 
The response of the biosensor as described in Example 1 
Was ?rst evaluated after protein immobilization and as a func 
tion of cell con?uency. After con?rmation of the inhibited 
response folloWing 24 h of cell groWth (i.e., diminished trans 
port of potassium through the con?uent monolayer), the cell 
based membranes Were exposed to concentrations of VEGF 
ranging from 100 pg/mL to 1 ug/mL (pH 7.0 in 0.1% BSA in 
PBS) for times ranging from 2 to 10 hr. The biosensor 
response Was measured for the folloWing conditions at a ?nal 
concentration of 0.1 M. KCl: (1) membrane Without cells or 
VEGF exposure to con?rm that the membrane response Was 
not affected by RGD; (2) membrane Without cells and With 
VEGF (1 ug/mL) to con?rm that the highest concentration of 
VEGF did not affect the response in the absence of HUVECs 
(FIGS. 3a, 4, and 5); (3) membrane With cells and Without 
VEGF to con?rm the inhibited sensor response after 24 h of 
cell groWth (FIGS. 3a, 4, and 5); and (4) membrane With cells 
and With varying concentrations of VEGF at different expo 
sure times. Data Were reported as a ratio of the potential 
response for ion-selective electrodes (1SEs) With HUVECs 
and/or VEGF to the potential response of the 1SEs Without 
HUVECs or VEGF for a ?nal concentration of 0.1 M KCl to 
account for slight variations betWeen fabricated membranes. 
Three to ?ve replicates Were performed for each VEGF con 
centration. 
Response of the biosensor to a high concentration ofVEGF 
(1 ug/mL) Was evaluated. Referring to FIG. 3, no signi?cant 
response from the sensor Was obtained at 2 and 4 hr of expo 
sure. Increasing the exposure time to 5 hr signi?cantly 
increased the response, and at 6 hr of exposure the response 
Was nearly double that of the 5 hrresponse period. Calibration 
curves for each exposure time supported these ?ndings (FIG. 
3b). 
It Was desired also to evaluate the loWer detection limit of 
the sensor. The biosensor of Example 1 Was exposed to a 
reduced concentration (100 ng/ml) of VEGF. Experimental 
conditions Were substantially as described previously. The 
response ratio Was very loW after exposing the biosensor to 
100 ng/ml of VEGF for 6 hr, but approximately tripled after 8 
hr (FIG. 4). Reducing the VEGF concentration to 1 ng/ml 
With an 8 hr exposure period resulted in a response ratio 
nearly equal to the control response (monolayer Without 
VEGF). HoWever, increasing the response time to 10 hr sig 
ni?cantly increased the response ratio (FIG. 5). 
Example 3 
The response ratio from the biosensor Was evaluated as a 
function of the concentration of VEGF. The sensor Was 
exposed to increasing concentrations (100, 300, and 600 
pg/ml) of VEGF, over a 10 hr exposure period based on the 
results described in Example 2. Referring to FIG. 6 (see the 
plot of “Obtained sensor values”), as the concentration of 
VEGF increased, the response ratio also increased. The curve 
shape Was characteristic of binding events shoWing a rapid 
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binding rate at lower cytokine concentrations, and reaching 
saturation at higher cytokine concentrations. Based on these 
data, the detection limit for the biosensor under these condi 
tions Was estimated to be 70 pg/ml. 
Example 4 
Detection of unknown concentrations of VEGF produced 
by cell lines Was evaluated also. For comparison, a conven 
tional immunoassay for VEGF Was used to detect VEGF in 10 
the samples. The medium Was assayed for VEGF using a 
Human Quantikine VEGF ELISA kit (R & D Systems, Min 
neapolis, Minn.) according to the manufacturer’s instruc 
tions. Samples Were analyZed at 450 nm using an El,C Univer 
sal Microplate Reader (Bio-Tek Instruments) With three 15 
replicates per cell line. Data are reported as mean concentra 
tion (pg/ml):SEM. Tu2% medium and MelM medium (see 
beloW) Were also assayed as controls. 
Human epidermal melanocytes (HEMs; ScienCell, San 
Diego, Calif.) Were cultured in MelM media (ScienCell) as 
8 
The data points for the ELISA assay fell Within the standard 
errors of the plot representing the biosensor model except at 
the loWest concentrations of VEGF. 
VEGF concentrations determined by the biosensor method 
and by ELISA are shoWn in Table 1. For the metastatic cell 
line (l205LU) at higher cell seeding densities (l X106 and 
5><l05 cells/Well), the biosensor gave results comparable to 
ELISA. The biosensor substantially predicted actual VEGF 
concentrations as measured by ELISA, and Was shoWn to 
respond to VEGF concentrations corresponding to docu 
mented concentrations of VEGF found in blood of cancer 
patients [Haggstrom et al. (2000) Prostate 45:42-50; Salven et 
al. (1998) Cancer 79:144-146; Duque et al. (1999) Urology 
54: 523-527 (all incorporated herein in their entirety by refer 
ence)]. Table 1 also shoWs that the nonmetastatic (WM 793) 
cells produced no detectable VEGF as measured by ELISA. 
Similarly, the biosensor results Were Within the range seen in 
the control studies (see FIGS. 3-5). By Way of con?rmation, 
normal HEMs produced no detectable VEGF by ELISA 
assay, and the biosensor produced no appreciable response. 
TABLE 1 
Comparison of in vitro VEGF production by various cell types. 
Seeding Final ELISA Predicted 
density concentration concentration Response ratio concentration from 
(cells/Well) (cells/ml) (pg/ml) from biosensor sensor (pg/ml) 
1205LU 1><106 1.1><106 387 1 25 0.32 1 0.02 339 1 80 
5 ><105 4.2 ><105 220 115 0.27 1 0.02 189 1 54 
1><105 2.4 ><105 17.4 1 3 7 0.08 1 0 0.86 1 0.4 
WM793 1><106 9.2 ><105 ND 0.03 1 0.01 0 
5 ><105 4.0 ><105 ND 0.04 1 0.01 0 
1><105 2.1 X 105 ND 0.05 1 0.02 0 
HEMs 1><105 5.3 ><105 ND 0.04 1 0 0 
TU2% N/A N/A ND 0.04 0 
MelM N/A N/A ND 0.05 0 
HUVEC N/A N/A NM 0.05 0 
0.1 N/A N/A NM 0.04 0 
W/v % 
BSA in 
PBS 
Data presented as means 1 SEM. 
ND = not detectable. 
NM = not measured. 
controls. Subculturing reagents Were trypsin/EDTA, TNS, 45 
and PBS. WM793 nonmetastatic melanoma cells (not 
expected to produce signi?cant quantities of VEGF) and 
l205LU metastatic melanoma cells (expected to produce 
VEGF) Were obtained from the laboratory of Dr. David Kaet 
Zel, University of Kentucky. These cells Were cultured in 50 
TU2% medium consising of MCDB 153 medium poWder 
(Sigma), LeibovitZ’s L-l5 medium poWder (Gibco, Invitro 
gen Corp.), FBS (Sigma), bovine insulin, sodium bicarbon 
ate, and calcium chloride. Subculturing reagents Were 
trypsin/EDTA and PBS. 55 
The cell lines Were cultured for 48 hr (groWth) in test Wells 
at various densities, and supernatant Was WithdraWn. Initial 
cell density Was controlled in each test Well, and the ?nal cell 
count Was determined to con?rm that the groWth rate of the 
cells Was consistent over the 48 hr period. After 48 hr of 60 
groWth, the biosensor Was exposed to the supernatant 
medium for 10 hr as described in Example 4. 
Concurrently, a VEGF ELI SA Was performed on the same 
supernatant medium samples. The ELISA results for the 
l205LU (metastatic) cells Were plotted against the biosensor 65 
response ratio (FIG. 6) to evaluate hoW closely the biosensor 
predicted the VEGF concentration as measured by ELISA. 
Accordingly, it has been shoWn that the biosensor of the 
present invention has a detection limit of at least 70 pg/ml. 
Using the molecular Weight of VEGF165 (42 kDa), this cor 
responds to a 2x10‘12 M detection limit. The biosensor can 
therefore be used to effectively screen for quantities of VEGF 
in biological samples, such as for example blood samples, 
from cancer patients. Since it is knoWn that VEGF levels in 
biological samples, including serum and plasma, are corre 
lated With the presence, metastasis, and disease stage of can 
cer (Haggstrom et al., 2000; Salven et al., 1998; Duque et al., 
1999), the biosensor of the present invention can be used to 
effectively screen for cancer. 
In comparison to conventional screening procedures such 
as biopsies, the method of the present invention is adaptable 
for use in a minimally invasive manner, and could be used as 
an early cancer screening tool by a physician during a routine 
o?ice visit. Further, the method of the present invention pro 
vides the further advantage of a rapid response time (10 hr or 
less), in comparison to a conventional biopsy procedure, 
Which may take a Week or more to schedule, perform the 
procedure, and report the results to the patient. 
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The foregoing description of the preferred embodiment of 
this invention has been presented for purposes of illustration 
and description. It is not intended to be exhaustive or to limit 
the invention to the precise form disclosed. Obvious modi? 
cations or variations are possible in light of the above teach 
ings. It Will be appreciated by the skilled artisan that the 
method may be adapted to a variety of combinations of cell 
types, analytes, and ions used in the biosensor, With the pro 
viso that the analyte or analytes be indicative or predictive of 
a cancer, and that permeability is induced in the particular cell 
type used. For example, different cell types could be incor 
porated into the biosensor of the invention, either alone or in 
combination, such as native endothelial cells, keratinocytes, 
lung cells, kidney cells, and the like, With the proviso that the 
cells form a layer that is substantially impervious to passage 
of the ion of choice absent contact With a permeability-induc 
ing analyte. 
Alternative membrane types are also contemplated by the 
present invention, including polymer membranes such as 
polyurethane, poly-(hydroxyethyl)methacrylate, poly(vinyl) 
chloride, and the like, Which may be utiliZed in order to 
improve cell adhesion or alter the mechanism of attachment 
of the bridging linker, With the proviso that the membrane is 
or can be made selective for the ion of choice. 
Still further, it Will be appreciated that the detected mol 
ecule need not be an ion, but may be any ionic or neutral 
molecule, With the proviso that the sensor is able to detect the 
molecule and the membrane is appropriately selective for the 
molecule. 
Still yet further, multiple biosensors comprising different 
cell types and membrane types, each being more or less 
sensitive to the presence of a particular cancer-inducing ana 
lyte, may be incorporated into a sensor array adapted for 
detection of multiple combinations of analytes, such as for 
example a combination of VEGF, tumor necrosis factor, and 
interleukin 8, to facilitate complete sample analysis and 
improve the predictive value of the method. 
The embodiment Was chosen and described to provide the 
best illustration of the principles of the invention and its 
practical application to thereby enable one of ordinary skill in 
the art to utiliZe the invention in various embodiments and 
With various modi?cations as are suited to the particular use 
contemplated. All such modi?cations and variations are 
Within the scope of the invention as determined by the 
appended claims When interpreted in accordance With the 
breadth to Which they are fairly, legally, and equitably 
entitled. 
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What is claimed is: 
1. A method for detecting an analyte, comprising: 
providing a biosensor comprising a live endothelial or epi 
thelial cell barrier Which is substantially impermeable to 
a potassium ion, a permeable membrane Which is selec 
tive for the potassium ion, and a detector capable of 
detecting the potassium ion; 
contacting the biosensor With a sample including at least 
one of the potassium ion and an analyte selected from at 
least one of a vascular endothelial groWth factor, a basic 
?broblast groWth factor, a hepatocyte groWth factor, and 
a tumor necrosis factor-0t, Wherein the analyte induces 
permeability of the live cell barrier and causes at least a 
portion of the potassium ion to pass through the live cell 
barrier and the membrane; and 
detecting the presence or absence of the potassium ion. 
2. The method of claim 1, Wherein the live cell barrier is a 
transformed human endothelial cell line. 
3. The method of claim 2, Wherein the live cell barrier is 
provided as a substantially con?uent cell monolayer Which is 
contiguous With the permeable membrane. 
4. The method of claim 3, Wherein the cell monolayer is 
substantially impermeable to the potassium ion, and becomes 
at least partially permeable upon contact With the analyte. 
5. The method of claim 1, including the step of coupling the 
detector to a transducer providing a measurable signal. 
6. The method of claim 1, Wherein the analyte is a vascular 
endothelial groWth factor. 
7. The method of claim 1, including the step of chemically 
modifying a permeable cellulose triacetate membrane to 
induce selectivity for the potassium ion. 
8. The method of claim 7, including chemically modifying 
the cellulose triacetate membrane With valinomycin to induce 
selectivity for potassium. 
9. A method for monitoring an analyte in a patient during a 
predetermined time interval, comprising: 
(1) obtaining a biological sample from a patient; 
(2) combining the biological sample With a predetermined 
amount of a potassium ion to form a mixture; and 
(3) contacting the mixture With a biosensor comprising: (a) 
a live endothelial or epithelial cell barrier Which is sub 
stantially impermeable to the potassium ion, (b) a per 
meable membrane Which is selective for the potassium 
ion, and (c) a detector capable of detecting the potassium 
ion; 
(4) detecting the presence or absence in the mixture of an 
analyte selected from at least one of a vascular endothe 
SEQUENCE LISTING 
SEQ ID NO 1 
LENGTH: 5 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: 
<400> SEQUENCE: 1 
Gly Arg Gly Asp Ser 
1 5 
synthetic RGD peptide sequence 
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lial growth factor, a basic ?broblast growth factor, a 
hepatocyte growth factor, and a tumor necrosis factor-0t, 
wherein the analyte causes the live cell barrier to become 
at least partially permeable to the potassium ion 
whereby the potassium ion passes through the live cell 
barrier and the membrane and is detected by the detec 
tor; 
(5) correlating the amount of the potassium ion detected 
with the quantity of the analyte in the biological sample; 
and 
(6) repeating steps 1 trough 5 after a predetermined time 
interval has passed. 
10. The method of claim 9, including selecting the biologi 
cal sample from the group consisting of serum, whole blood, 
plasma, a tissue biopsy, an organ biopsy, lymphatic ?uid, 
saliva, tears, milk, urine, and any combination thereof. 
5 
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11. The method of claim 9, wherein the live cell barrier 
comprises a transformed human endothelial cell line. 
12. The method of claim 11, including providing the live 
cell barrier as a substantially con?uent monolayer which is 
contiguous with the permeable membrane. 
13. The method of claim 9, including coupling the detector 
to a transducer providing a detectable signal. 
14. The method of claim 9, wherein the analyte is a vascular 
endothelial cell growth factor. 
15. The method of claim 9, including the step of chemically 
modifying a permeable cellulose triacetate membrane to 
induce selectivity for the potassium ion. 
16. The method of claim 15, including chemically modi 
fying the cellulose triacetate membrane with valinomycin to 
induce selectivity for potassium. 
* * * * * 
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